Are you an oncologist who is passionate about educating fellow providers? We invite you to apply to join the Binaytara Foundation Education Academy! Members will be involved in the planning and implementation of the educational activities of the Foundation, including Hematology/Oncology meetings, the International Journal of Cancer Care & Delivery (IJCCD), and the educational game. Our Education Academy Chairs, Drs. Sid Yadav and Sri Tantravahi, have formed the following subcommittees:
To apply, please email [email protected] with your CV and a letter expressing your area of interest.
Terms and responsibilities:
Binaytara Foundation (BTF) is a global cancer non-profit committed to minimizing cancer disparities through education, advocacy, and innovation. Our projects include a multi-channel hematology and oncology education program focused on educating healthcare providers and cancer patients about the most recent advances in cancer care and a global oncology program focused on developing sustainable cancer programs and services in resource-poor communities.
BTF Education Academy members are instrumental in achieving our goal of improving access to cancer care. Your participation will have an impact for years to come. Apply today!
2022 Summit on Cancer Health Disparities ASCO award Binaytara foundation Binaytara Foundation Cancer Center Binaytara Foundation education academy breast cancer BTF cancer cancer care cancer disparities cancer research cancer treatment cancer treatment in Nepal CME community oncologists conference Conferences continuing education Dr. Binay Shah Dr. Rubina Suwal events Expert Opinion faculty faculty highlight FDA approved Featured head & neck cancer surgery in Nepal healthcare equity hematological malignancies Journal leukemia Lung cancer lymphoma multiple myeloma Nepal Nepal cancer care oncology oncology CME Opinion peer-reviewed journal SCHD upcoming conferences video news Volunteer
By Dr. Inas Abuali Massachusetts General Hospital There is a paucity of available treatment options for patients with advanced papillary renal
MoreOn March 4, 2023, the U.S. Food and Drug Administration approved expanded use of adjuvant abemaciclib with endocrine therapy for adult patients
MoreBy Dr. Chepsy Philip Believers Church Medical College Hospital Care of hematological cancers in India and other low- and middle-income countries
MoreOn February 9th, 2023, the U.S. Food and Drug Administration approved dostarlimab-gxly for adult patients with recurrent or advanced endometrial cancer (EC)
MoreDr. Daneng Li of City of Hope Comprehensive Cancer Center shares a recent abstract from ASCO GI, NRG/RTOG 1112, a randomized phase
More